Premium
The Uricosuric Effect of Oxaprozin in Humans
Author(s) -
Goldfarb Stanley,
Walker Barry R.,
Agus Zalman S.
Publication year - 1985
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1985.tb02815.x
Subject(s) - uricosuric , uric acid , chemistry , excretion , medicine , endocrinology , urinary system , prostaglandin , renal function , pharmacology , diuretic , hyperuricemia , biochemistry
The effects of oxaprozin, a new investigational propionic acid analogue, and indomethacin on uric acid metabolism were compared in 12 healthy volunteers receiving either agent, first as a single dose and then daily for seven days. While indomethacin did not alter either serum or urinary uric acid values, oxaprozin caused a fall in serum uric acid levels from 5.8 ± 0.2 mg/dL to 4.8 ± 0.4 mg/dL (P < 0.01). Urinary uric acid excretion rose from a baseline of 673 ± 47 mg to 825 ± 66 mg/24 h by day 7 of treatment (P < 0.01). Since oxaprozin was associated with no change in glomerular filtration rate in these studies, the hypouricemic effect of oxaprozin is most likely a result of its direct uricosuric action. Because indomethacin and oxaprozin both are inhibitors of urinary prostaglandin E 2 excretion, the data suggest that prostaglandin inhibition per se is not associated with changes in uric acid excretion.